Dr. Kandzari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
95 Collier Rd NW
Ste 2065
Atlanta, GA 30309Phone+1 404-605-2800Fax+1 404-720-0911
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1998 - 2002
- Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
- Duke University School of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 2008 - Present
- GA State Medical License 2010 - 2026
- TX State Medical License 2008 - 2011
- NC State Medical License 1999 - 2008
- VA State Medical License 2004 - 2006
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- Atlanta Magazine: Top Doctors Castle Connolly, 2011-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Join now to see all
Clinical Trials
- Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations. Start of enrollment: 2005 Nov 01
- Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease. Start of enrollment: 2005 Dec 01
- CYPRESS - CYPHER for Evaluating Sustained Safety Start of enrollment: 2009 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 125 citationsDefinitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.Luiz F. Ybarra, Stéphane Rinfret, Emmanouil S. Brilakis, Dimitri Karmpaliotis, Lorenzo Azzalini
Circulation. 2021-02-02 - 230 citationsGuiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention: A Global Expert Consensus DocumentEmmanouil S. Brilakis, Kambis Mashayekhi, Etsuo Tsuchikane, Nidal Abi Rafeh, Khaldoon Alaswad
Circulation. 2019-07-30 - 118 citationsApplication and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registryGeorgios Christopoulos, Dimitri Karmpaliotis, Khaldoon Alaswad, Robert W. Yeh, Farouc A. Jaffer
International Journal of Cardiology. 2015-11-01
Journal Articles
- Original Investigations Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year ResultsDavid E Kandzari, Ron Waksman, Donald E Cutlip, Elie G Gharib, ScienceDirect
- Original Investigation Left Main Revascularization with PCI or CABG in Patients with Chronic Kidney Disease: EXCEL TrialJohn D Puskas, David E Kandzari, Gennaro Giustino, Roxana Mehran, Martin B Leon, Philippe Genereux, Michael 3rd Ragosta, Charles A Simonton, Irving L Kron, Gregg W Stone, ScienceDirect
- Focus on Left Main Interventions Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site: Results f...Gregg W Stone, David E Kandzari, Nicholas J Lembo, ScienceDirect
- Join now to see all
Lectures
- Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the ...Society for Cardiovascular Angiography and Interventions, Phoenix, Arizona - 1/19/2013
- The Target BP Program: Ongoing and Future StudiesCRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/27/2019
- Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes!CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
- Join now to see all
Authored Content
- Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
- Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
- The Day After a Primary EndpointMarch 2018
- New-Onset Atrial Fibrillation After PCI or CABG for Left Main DiseaseFebruary 2018
- New-Onset Atrial Fibrillation After PCI or CABG for Left Main DiseaseFebruary 2018
- New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease the EXCEL TrialFebruary 2018
- New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease the EXCEL TrialFebruary 2018
- Join now to see all
Press Mentions
- SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two YearsOctober 28th, 2024
- Medtronic’s Symplicity Spyral RDN Evaluated at 2 Years in SPYRAL HTN-ON MEDOctober 28th, 2024
- Cover Story | Renal Denervation: Expanding Care for Treatment-Resistant HypertensionAugust 30th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: